Chapter Seven - Moxifloxacin Hydrochloride
Section snippets
Systematic chemical names
1-Cyclopropyl-6-fluoro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid hydrochloride [1].
1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-3-quinolinecarboxylic monohydrochloride [2].
(4aS-cis)-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[-octahydro-6H-pyrrolo [3,4-b] pyridin-6-yl]-4-oxo-3-quinolinecarboxylic monohydrochloride [2].
1-cyclopropyl-7-[(S,S
Method I [10–12]
l-Cyclopropyl-6,7-difluoro-8-methoxy-l,4-dihydro-4-oxo-3-quinolinecarboxylic acid (I) is condensed with cis [S,S]-2,8-diazabicyclo[4.3.0]nonane (II) under reflux in a mixture of acetonitrile and dimethylformamide in the presence of 1,4-diazabicyclo [2.2.2]octane (DABCO) as a catalyst to get moxifloxacin base. The later compound is dissolved in HCl solution by means of heat, then concentrated, cooled, and precipitated by ethanol to give moxifloxacin HCl (Scheme 7.1). For further purification, it
Ionization constants
Moxifloxacin is an amphoteric compound, which contains a secondary alkyl amine, two tertiary arylamines, and a carboxylic acid (Figure 7.1).
The ionization constants (pKa1 and pKa2) were measured by means of potentiometry and spectrophotometry [27]. The obtained two pKa values were 6.25 and 9.29 for carboxylic acid and secondary amine, respectively. The low acidic character of moxifloxacin was explained by the formation of intramolecular hydrogen bond between the carboxyl and keto groups in the
Moxifloxacin HCl drug substance
Moxifloxacin HCl is a drug substance listed in the European pharmacopeia (Ph. Euro.) [1], United States pharmacopeia-national formulary (USP-NF) [2] and United States pharmacopeia-medicines compendium (USP-MC) [57]. Table 7.15 shows its summary of specifications and methods of analysis.
In addition to the mentioned “Reference Procedure” (Table 7.15), the USP-MC monograph includes the criteria-based procedures necessary to demonstrate that an “Acceptable Procedure” is equivalent to the “Reference
Solid-state stability
Forced degradation of moxifloxacin HCl in solid state was investigated by using densitometric TLC method [104]. It was found that heating moxifloxacin HCl at 100 °C for 8 h leads to a decrease in percentage recovery to 91% with the detection of three degrades.
Stability of moxifloxacin HCl in its tablet dosage form after incubation at 40 °C/75% RH and 50 °C/75% RH for 6 months was investigated using HPLC/UV detection [143]. The stability data for two products (Avelox® and Staxin®) proved that the
Systemic use
Moxifloxacin HCl is a fluoroquinolone antibacterial indicated for treating infections in adults caused by designated, susceptible bacteria. It was initially approved in a tablet form by the EMA in June 1999 [185] and by the USFDA in December 1999 [186].
Moxifloxacin HCl tablets and intravenous are indicated in patients aged 18 years and older for the treatment of the following bacterial infections if they are caused by bacteria susceptible to moxifloxacin:
- −
Acute bacterial sinusitis
- −
Acute
References (198)
- et al.
Spectroscopic studies, thermal analyses and biological evaluation of new V(IV), Zr(IV) and U(VI) moxifloxacin complexes
J. Mol. Struct.
(2011) - et al.
Highly efficient racemisation of a key intermediate of the antibiotic moxifloxacin
Tetrahedron: Asymmetry
(2011) - et al.
Protonation equilibrium and lipophilicity of moxifloxacin
J. Pharm. Biomed. Anal.
(2005) - et al.
Pharmacokinetics and milk benetration of moxifloxacin after intramuscular administration to lactating goats
Vet. J.
(2007) - et al.
Enantiomeric purity assay of moxifloxacin hydrochloride by capillary electrophoresis
J. Pharm. Biomed. Anal.
(2005) - et al.
Vibrational spectroscopic characterization of fluoroquinolones
Spectrochim. Acta A Mol. Biomol. Spectrosc.
(2005) - et al.
Separation and identification of moxifloxacin impurities in drug substance by high-performance liquid chromatography coupled with ultraviolet detection and Fourier transform ion cyclotron resonance mass spectrometry
Chin. Chem. Lett.
(2012) - et al.
Validated spectrophotometric methods for the estimation of moxifloxacin in bulk and pharmaceutical formulations
Spectrochim. Acta A Mol. Biomol. Spectrosc.
(2007) Atomic absorption spectroscopic, conductometric and colorimetric methods for determination of some fluoroquinolone antibacterials using ammonium reineckate
Spectrochim. Acta A Mol. Biomol. Spectrosc.
(2008)Spectrofluorimetric determination of fluoroquinolones in pharmaceutical preparations
Spectrochim. Acta A Mol. Biomol. Spectrosc.
(2009)